AbbVie has announced that the Irish health authorities have approved reimbursement of PRODUODOPA® (foslevodopa/foscarbidopa) for the treatment of advanced levodopa-responsive
Read more
End-of-trial data show 79.7% efficacy in participants aged 50 years and over during long-term follow-up, six to 11 years after
Read more
Eli Lilly and Company announced that the European Commission (EC) granted marketing authorization (MA) on 19 April 2024 for tirzepatide
Read more
Following a 30-year joint venture, Sandoz, the world’s largest generics and biosimilars company, has acquired full ownership of Rowex. Rowex
Read more
Dostarlimab plus chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival (OS) in the
Read more
Astellas Pharma recently announced results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for enfortumab vedotin in
Read more
The International Canoe Federation’s (ICF) Women’s Paddlesports Symposium, hosted by Canoeing Ireland concluded with participants from 34 countries agreeing to actions
Read more
Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,
Read more
Approval for AKEEGA® is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study that includes the largest cohort to
Read more
Clonmel Healthcare is delighted to announce the launch of Ranolazine Clonmel 375mg, 500mg and 750mg prolonged-release tablets. Full prescribing information
Read more